Hyloris Pharmaceuticals (LTS:0AB6) LT-Debt-to-Total-Asset: 0.04 (As of Dec. 2025)

What is Hyloris Pharmaceuticals LT-Debt-to-Total-Asset?

Hyloris Pharmaceuticals LTS:0AB6 63 LT-Debt-to-Total-Asset is 0.04 as of Dec. 2025. GuruFocus rates LTS:0AB6 with a GF Score™ of 63/100 and a GF Value™ of €9.56 (Possible Value Trap). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Hyloris Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.04.

Hyloris Pharmaceuticals's long-term debt to total assets ratio increased from Dec. 2024 (0.04) to Dec. 2025 (0.04). It may suggest that Hyloris Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Hyloris Pharmaceuticals (LTS:0AB6) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Hyloris Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Hyloris Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Hyloris Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyloris Pharmaceuticals LT-Debt-to-Total-Asset Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.01

0.03

0.04

Hyloris Pharmaceuticals Semi-Annual Data
	Dec16	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial												0.03	0.04	0.04	0.04	0.04

63GF Score

Hyloris Pharmaceuticals SA LTS:0AB6

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Hyloris Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Hyloris Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1.246	/	33.357
	=	0.04

Hyloris Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	1.246	/	33.357
	=	0.04

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.04 mean?

Hyloris Pharmaceuticals (LTS:0AB6) has a LT-Debt-to-Total-Asset of 0.04 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hyloris Pharmaceuticals and its competitors.

Is Hyloris Pharmaceuticals' LT-Debt-to-Total-Asset too high?

Hyloris Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.04. Overall, Hyloris Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Hyloris Pharmaceuticals' LT-Debt-to-Total-Asset compare to VRTX and REGN?

Hyloris Pharmaceuticals' LT-Debt-to-Total-Asset of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Hyloris Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.56, compared to a current price of €4.53 — trading 52.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.04. Hyloris Pharmaceuticals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current LT-Debt-to-Total-Asset is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.53 is trading 52.6% below its estimated GF Value™ of €9.56. GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LTS:0AB6:

LT-Debt-to-Total-Asset: 0.04
GF Value™: €9.56 vs. price of €4.53 (52.6% below fair value)
GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyloris Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies XBRU:ONWD XBRU:ALEMS XBRU:CYAD XBRU:OXUR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA XKRX:068270 RPRX ROIV BNTX INCY INSM

Other Exchanges 52U:Germany HYL:Belgium

Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000

Website https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.

63GF Score

Get the complete analysis for LTS:0AB6

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.53

Price

€9.56

GF Value

View LTS:0AB6 Analysis

See LT-Debt-to-Total-Asset data for all stocks →